Teleflex (NYSE:TFX) Stock Unloaded Rep. Lisa C. McClain

Key Points

• Representative Lisa C. McClain sold between $1,001 and $15,000 in shares of Teleflex (NYSE:TFX) on July 22, 2025, according to a filing.
• Teleflex's latest earnings report showed an EPS of $3.73, surpassing the consensus estimate of $3.36, with revenue of $780.90 million.
• The company declared a quarterly dividend of $0.34 per share, representing an annualized yield of 1.1%, payable on September 15, 2023.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Teleflex Incorporated NYSE: TFX. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Teleflex stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Teleflex Stock Performance

Teleflex stock traded down $0.16 during mid-day trading on Friday, reaching $121.01. 36,141 shares of the company's stock were exchanged, compared to its average volume of 795,664. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42. The business's fifty day simple moving average is $117.97 and its 200 day simple moving average is $133.22. Teleflex Incorporated has a one year low of $108.90 and a one year high of $249.90. The firm has a market capitalization of $5.35 billion, a PE ratio of 28.46, a P/E/G ratio of 1.71 and a beta of 1.08.

Teleflex (NYSE:TFX - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.36 by $0.37. The business had revenue of $780.90 million during the quarter, compared to the consensus estimate of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%. The firm's revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.42 EPS. On average, sell-side analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 15th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Friday, August 15th. Teleflex's dividend payout ratio (DPR) is 32.00%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada boosted their target price on Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a research note on Friday, August 1st. Mizuho upped their target price on Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a report on Friday, August 1st. Wells Fargo & Company cut their price target on Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. Morgan Stanley lowered their price objective on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research report on Monday, May 5th. Finally, Truist Financial lowered their price objective on Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a research report on Monday, May 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Teleflex currently has an average rating of "Hold" and a consensus price target of $141.57.

Hedge Funds Weigh In On Teleflex

Several institutional investors have recently bought and sold shares of TFX. Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Teleflex by 242.9% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company's stock worth $26,000 after buying an additional 153 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in Teleflex by 103.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 100 shares during the period. Banque Cantonale Vaudoise acquired a new position in shares of Teleflex in the first quarter worth about $27,000. Costello Asset Management INC acquired a new position in shares of Teleflex in the first quarter worth about $28,000. Finally, Brooklyn Investment Group raised its position in shares of Teleflex by 258.6% during the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock worth $29,000 after purchasing an additional 150 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Stuart A. Randle purchased 1,000 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average price of $115.86 per share, with a total value of $115,860.00. Following the purchase, the director directly owned 7,547 shares in the company, valued at approximately $874,395.42. This represents a 15.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jaewon Ryu purchased 1,500 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was purchased at an average cost of $115.00 per share, with a total value of $172,500.00. Following the purchase, the director owned 3,727 shares in the company, valued at approximately $428,605. This trade represents a 67.36% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 5,500 shares of company stock worth $633,590. Company insiders own 1.40% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.